EWI2 and its relatives in Tetraspanin-enriched membrane domains regulate malignancy

Area of Science:

• Molecular biology
• Cancer research
• Immunology

Background:

• The immunoglobulin superfamily (IgSF) member EWI2 exhibits complex roles in cancer.
• EWI2 suppresses solid tumors like brain, lung, skin, and prostate cancers.
• EWI2 supports myeloid leukemia and maintains leukemia stem cells.

Purpose of the Study:

• To elucidate the multifaceted roles of EWI2 and its relatives in malignant diseases.
• To explore the mechanisms underlying EWI2's impact on tumor growth and metastasis.
• To assess the therapeutic potential of EWI2 subfamily members in cancer treatment.

Main Methods:

• In vitro and in vivo experimental studies.
• Bioinformatics analyses of gene expression.
• Investigation of EWI2's mechanism involving tetraspanin-enriched membrane domains (TEMDs).
• Analysis of EWI2's modulation of nuclear translocation of ERK and TFEB.

Main Results:

• EWI2 inhibits solid tumor growth and cell movement but promotes myeloid leukemia.
• EWI2 gene expression is downregulated in glioblastoma but upregulated in melanoma, pancreatic, and liver cancers.
• EWI2 acts by inhibiting growth factor receptors and cell adhesion proteins via TEMDs.
• EWI2 influences gene expression regulators ERK and TFEB.

Conclusions:

• EWI2 and its relatives are significant regulators of cancer, with context-dependent effects.
• The impact of EWI2 subfamily members on tumors depends on the specific molecular network and TEMD composition.
• EWI2 and related proteins show promise as anti-cancer therapeutics and targets.